Severe Diltiazem Poisoning Managed With CytoSorb Hemoadsorption and Supportive Therapies: A Case Report.

IF 2.9 Q4 Medicine
Critical care explorations Pub Date : 2026-08-03 eCollection Date: 2026-08-01 DOI:10.1097/CCE.0000000000001454
Juul M Cox, Julia A M Verwaaijen, Ruben M F Hendriks, Dorien Smeets, Suzanne van Rijswijk, Tessa M Bosch
{"title":"Severe Diltiazem Poisoning Managed With CytoSorb Hemoadsorption and Supportive Therapies: A Case Report.","authors":"Juul M Cox, Julia A M Verwaaijen, Ruben M F Hendriks, Dorien Smeets, Suzanne van Rijswijk, Tessa M Bosch","doi":"10.1097/CCE.0000000000001454","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Severe intoxication with nondihydropyridine calcium channel blockers, such as diltiazem, is associated with high morbidity and mortality. Evidence supporting extracorporeal treatment strategies remains limited. This case integrates serial toxicokinetic measurements with adjunctive hemoadsorption in sustained-release diltiazem poisoning.</p><p><strong>Case summary: </strong>A 73-year-old man presented with coma, complete atrioventricular block, refractory hypotension, and severe lactic acidosis. Despite optimized supportive therapy including vasopressors, calcium supplementation, hyperinsulinemic-euglycemic therapy, and continuous renal replacement therapy, he remained hemodynamically unstable. CytoSorb hemoadsorption was initiated 6 hours after ICU admission. Shortly thereafter, sinus rhythm was restored, serum lactate rapidly declined, and vasopressor and insulin requirements were progressively reduced, allowing discontinuation of extracorporeal support. The patient recovered and was discharged home.</p><p><strong>Conclusions: </strong>Retrospective analysis demonstrated elevated diltiazem concentrations with delayed, capacity-limited elimination. This case supports considering hemoadsorption in unstable patients with severe diltiazem poisoning despite conventional measures and highlights the need for systematic pharmacokinetic evaluation in future studies.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":"8 8","pages":"e1454"},"PeriodicalIF":2.9000,"publicationDate":"2026-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13433092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical care explorations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CCE.0000000000001454","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Severe intoxication with nondihydropyridine calcium channel blockers, such as diltiazem, is associated with high morbidity and mortality. Evidence supporting extracorporeal treatment strategies remains limited. This case integrates serial toxicokinetic measurements with adjunctive hemoadsorption in sustained-release diltiazem poisoning.

Case summary: A 73-year-old man presented with coma, complete atrioventricular block, refractory hypotension, and severe lactic acidosis. Despite optimized supportive therapy including vasopressors, calcium supplementation, hyperinsulinemic-euglycemic therapy, and continuous renal replacement therapy, he remained hemodynamically unstable. CytoSorb hemoadsorption was initiated 6 hours after ICU admission. Shortly thereafter, sinus rhythm was restored, serum lactate rapidly declined, and vasopressor and insulin requirements were progressively reduced, allowing discontinuation of extracorporeal support. The patient recovered and was discharged home.

Conclusions: Retrospective analysis demonstrated elevated diltiazem concentrations with delayed, capacity-limited elimination. This case supports considering hemoadsorption in unstable patients with severe diltiazem poisoning despite conventional measures and highlights the need for systematic pharmacokinetic evaluation in future studies.

用CytoSorb血液吸附和支持疗法治疗重度地尔硫卓中毒1例。
背景:非二氢吡啶类钙通道阻滞剂(如地尔硫卓)严重中毒与高发病率和死亡率相关。支持体外治疗策略的证据仍然有限。这个案例整合了一系列的毒性动力学测量和辅助血液吸附在缓释地尔硫卓中毒。病例总结:一名73岁男性,表现为昏迷、完全性房室传导阻滞、难治性低血压和严重乳酸性酸中毒。尽管优化了支持治疗,包括血管加压剂、补钙、高胰岛素-血糖治疗和持续肾脏替代治疗,他的血流动力学仍然不稳定。在ICU入院后6小时开始CytoSorb血液吸附。此后不久,窦性心律恢复,血清乳酸迅速下降,血管加压素和胰岛素需求逐渐降低,可以停止体外支持。病人痊愈出院回家了。结论:回顾性分析表明,地尔硫卓浓度升高具有延迟、清除能力有限的特点。本病例支持考虑对不稳定的严重地尔硫卓中毒患者进行血液吸附治疗,并强调在未来的研究中需要进行系统的药代动力学评价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.70
自引率
0.00%
发文量
0
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书